"The JAK2 V617F mutation is the most common driver gene in myeloproliferative neoplasm (MPN), which means that the JAK/STAT signaling pathway is persistently activated independent of cytokines, and plays an important part in the onset and development of MPN. The JAK inhibitors, although widely used in the clinical practice, are unable to eradicate MPN. Therefore, the unavoidable long-term treatment poses a serious burden for patients with MPN. It is established that the JAK2 V617F mutation, in addition its role in the JAK/STAT pathway, can promote cell proliferation, differentiation, anti-apoptosis, DNA damage accumulation, and other key biologic processes through multiple pathways. Other than that, the JAK2 V617F mutation affects the cardiovascular system through multiple mechanisms. Although JAK inhibitors cannot eradicate MPN cells, the combined use of JAK inhibitors and other drugs may have surprising effects. This requires an in-depth understanding of the mechanism of action of the JAK2 V617F mutation. In this review, the authors explored the role of the JAK2 V617F mutation in MPN from multiple aspects, including the mechanisms of non-JAK/STAT pathways, the regulation of cellular methylation, the induction of cellular DNA damage accumulation, and effects on the cardiovascular system, with the objective of providing valuable insights into multidrug combination therapy for MPN."
New advances in the role of JAK2 V617F mutation ... - MPN Voice
New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms
Interesting article, thank you for posting it. It is also interesting to see they indicate that taking statins can be helpful. I am currently taking a statin but read a lot of the debate about them beforehand and thought I had read somewhere they may help those of us with an mpn and this confirms it, so I will keep taking them.
Thanks for posting
Is there a free version of this article?
I saw the authors of the article, all of whom are Chinese doctors. As I am located in China, I may have a better understanding of Chinese doctors. These doctors are not well-known, and the combination of inhibitors with other medicines has actually been popular in China for a long time. Professor Chang Chunkang, he locals at Shanghai, is the first and earliest doctor in China to use inhibitors in combination with other medicines, and now his MPN patients are increasing and lots, and the effects are quite good.
Seems worth a deeper read. But most of us have no access and the abstract has no new info. One item in it "..JAK inhibitors cannot eradicate MPN cells" was the consensus till recently and is now not entirely true. We've discussed this report:
"A profound and durable MR (DMR; defined as a VAF stably ≤2%) including complete MR in 8%, was achieved in 20% of the patients"
CURCUMIN? – IS IT THE NEXT BEST THING...?
Update 7.1 - Very Good News
Researchers discover new genetic mutation in MPN.
